SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.

Abstract excerpt

Over the last decade, targeted inhibition of Bruton's tyrosine kinase (BTK) has led to a paradigm shift in the way chronic lymphocytic leukemia (CLL) is managed. BTK inhibitors (BTKi) are broadly classified as covalent BTKI and noncovalent BTKi (cBTKi and ncBTK) Ibrutinib, as the first approved cBTKi, vastly improved outcomes for patients with CLL over prior chemoimmunotherapy regimens. However, long-term use is...

Topics

Join the communities discussing this publication.

• Agammaglobulinaemia Tyrosine Kinase
• Leukemia, Lymphocytic, Chronic, B-Cell
• Longitudinal Studies
• Mutation
• Protein Kinase Inhibitors